Immutep Receives A$3.6 million R&D Tax Incentive from French Government
24 Setembro 2024 - 9:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the
Company”), a biotechnology company developing novel LAG-3 related
immunotherapy treatments for cancer and autoimmune diseases, is
pleased to announce it has received a €2,194,918 (~ A$3,627,980 )
research and development (R&D) tax incentive payment in cash
from the French Government under its Crédit d’Impôt Recherche
scheme (CIR).
The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax
Credit”, is a French government tax incentive by which French
companies conducting research and development activities in Europe
can be reimbursed 30% of their eligible expenditure.
Immutep qualifies for the CIR tax incentive through its
subsidiary Immutep S.A.S. due to the research and development
conducted in its laboratory in France. The cash payment is provided
in respect of expenditure incurred on eligible R&D activities
conducted in the European Union in the 2023 calendar year. Immutep
also qualifies for cash rebates from the Australian Federal
Government’s R&D tax incentive program in respect of
expenditure incurred on eligible R&D activities conducted in
Australia.
The funds will be used to support the ongoing and planned global
clinical development of eftilagimod alpha and IMP761.
About ImmutepImmutep is a
clinical-stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian Investors/Media:Catherine Strong,
Citadel-MAGNUS+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Investors/Media:Chris Basta, VP, Investor
Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Immutep (NASDAQ:IMMP)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
